<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31106" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Verapamil</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fahie</surname>
            <given-names>Sequoya</given-names>
          </name>
          <aff>St. Johns University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sequoya Fahie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31106.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The Food and Drug Administration (FDA) approved indications for verapamil include angina (chronic stable, vasospastic or Prinzmetal variant), unstable angina (crescendo, preinfarction), hypertension as add-on therapy, paroxysmal supraventricular tachycardia (PSVT) prophylaxis, and supraventricular tachycardia (SVT). Verapamil also has numerous non-FDA-approved indications. This activity outlines the indications, mechanism of action, administration methods, significant adverse effects, contraindications, toxicity, and monitoring, of verapamil so providers can direct patient therapy where it is indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of verapamil.</p></list-item><list-item><p>Summarize the approved and off-label indications for verapamil.</p></list-item><list-item><p>Identify the potential adverse effects associated with therapy with verapamil.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to properly use typhoid verapamil to improve patient outcomes for indicated conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31106&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31106">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31106.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>The Food and Drug Administration (FDA) Approved Indications for Verapamil are as Follows</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Angina (chronic stable, vasospastic [prinzmetal variant], unstable angina [cresendo,preinfarction])&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypertension (as add on therapy)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Paroxysmal supraventricular tachycardia (PSVT) prophylaxis</p>
          </list-item>
          <list-item>
            <p>Supraventricular tachycardia (SVT)</p>
          </list-item>
        </list>
        <p>
<bold>The non-FDA-approved Indications for Verapamil are as Follows</bold>
</p>
        <p>
<bold>Acute Coronary Syndrome (ACS)</bold>
</p>
        <p>Given as initial treatment in patients with: (1) Non-ST elevation acute coronary syndrome(NSTE-ACS, (2) continuing or frequently recurring ischemia and are unable to use beta-blockers (e.g., contraindication, suffered from unacceptable adverse effects, beta-blockers were insufficient for treatment) in the absence of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinically significant LV dysfunction,</p>
          </list-item>
          <list-item>
            <p>Increased risk for cardiogenic shock,</p>
          </list-item>
          <list-item>
            <p>PR interval greater than 24 seconds, or</p>
          </list-item>
          <list-item>
            <p>Second or third-degree AV block without a cardiac pacemaker</p>
          </list-item>
        </list>
        <p>Furthermore, long-acting calcium channel blockers and nitrates are recommended in patients with coronary artery spasm (short-acting calcium channel antagonists should be avoided).<xref ref-type="bibr" rid="article-31106.r1">[1]</xref></p>
        <p>
<bold>Cluster Headaches </bold>
</p>
        <p>Verapamil can be used as a first-line prophylactic at a minimum dosage of 240 mg per day per recommendation to reduce headache severity and decrease the frequency of episodes during a cluster period.<xref ref-type="bibr" rid="article-31106.r2">[2]</xref></p>
        <p>
<bold>Hypertrophic Cardiomyopathy (HCM)</bold>
<xref ref-type="bibr" rid="article-31106.r3">[3]</xref>
</p>
        <p>Recommended for the treatment of symptoms (e.g., angina or dyspnea) in patients with obstructive or non-obstructive HCM who are unable to take beta-blockers (e.g., side effects/contraindications to beta-blockers, unresponsive to beta-blockers).</p>
        <list list-type="bullet">
          <list-item>
            <p>Should be initiated at a low dose and titrated up to 480 mg/day,</p>
          </list-item>
          <list-item>
            <p>Its use requires caution in patients with high gradients, advanced heart failure, or sinus bradycardia.</p>
          </list-item>
        </list>
        <p>
<bold>Idiopathic Ventricular Tachycardia (IVT)</bold>
</p>
        <p>There are reports that the chronic use of oral verapamil for verapamil-sensitive idiopathy LVT can control IVT in many patients in both adults and children.<xref ref-type="bibr" rid="article-31106.r4">[4]</xref></p>
      </sec>
      <sec id="article-31106.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Verapamil is a non-dihydropyridine calcium channel blocker. Calcium channel blockers inhibit the entry of calcium ions into the slow L-type calcium channels in the myocardium and vascular smooth muscle during depolarization. This inhibition will produce relaxation of coronary vascular smooth muscle as well as coronary vasodilation, which is helpful in patients with hypertension. Verapamil also increases myocardial oxygen delivery, which helps patients with vasospastic angina. Verapamil correlates with negative chronotropic effects and decreased sympathetic nervous system activity.<xref ref-type="bibr" rid="article-31106.r5">[5]</xref><xref ref-type="bibr" rid="article-31106.r6">[6]</xref></p>
      </sec>
      <sec id="article-31106.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Verapamil can be administered either orally (sustained release or immediate release) or intravenously. It is possible to open sustained-release verapamil capsules, and the contents are sprinkled on one tablespoon of applesauce. Patients should receive instructions to swallow immediately with a full&#x000a0;glass of cool water. For&#x000a0;sustained verapamil products, take with food and swallow whole (they should not be chewed or crushed). When given intravenously, verapamil administration must be over at least a two-minute timeframe.&#x000a0;</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For immediate-release formulations, the usual dose range is 120 to 360 mg/day given in three divided doses; the maximum dose is 480 mg/day.<xref ref-type="bibr" rid="article-31106.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>For geriatric patients, consider lower initial doses and titrate to response.<xref ref-type="bibr" rid="article-31106.r8">[8]</xref>
<list list-type="bullet"><list-item><p>For immediate-release oral formulations, the initial dose is 40 mg three times daily (TID).</p></list-item><list-item><p>For extended-release oral formulations, give an initial dose of 120 mg once daily in the morning or 100 mg once daily at bedtime.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Angina</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For oral dosing, verapamil (immediate-release) should be given 80 mg to 160 mg three times a day (TID).<xref ref-type="bibr" rid="article-31106.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Atrial Fibrillation (AF)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous<xref ref-type="bibr" rid="article-31106.r10">[10]</xref>
<list list-type="bullet"><list-item><p>Administer an initial bolus of 0.075 to 0.15 mg/kg over at least 2 minutes.</p></list-item><list-item><p>If the patient does not produce an&#x000a0;adequate response, administer an additional 10 mg after 15 to 30 minutes.</p></list-item><list-item><p>If the patient produces an adequate response to the initial (or repeat bolus) dose, initiate a continuous infusion.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Oral<xref ref-type="bibr" rid="article-31106.r11">[11]</xref>
<list list-type="bullet"><list-item><p>For extended-release formulations, initiate a maintenance dose of 180 to 480 mg once daily.&#x000a0;</p></list-item><list-item><p>For immediate release formulations, initiate a dose of 240 to 480 mg daily in 3 to 4 divided doses; the maximum daily dose should be 480 mg/day.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>IVT</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous&#x000a0;
<list list-type="bullet"><list-item><p>Administer 2.5 to 5.0 mg every 15 to 30 minutes<xref ref-type="bibr" rid="article-31106.r12">[12]</xref><xref ref-type="bibr" rid="article-31106.r13">[13]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Oral&#x000a0;
<list list-type="bullet"><list-item><p>For immediate-release, formulations administer 360 mg/day in three divided doses.</p></list-item><list-item><p>For extended-release formulations, administer 240 to 480 mg once daily.<xref ref-type="bibr" rid="article-31106.r14">[14]</xref><xref ref-type="bibr" rid="article-31106.r15">[15]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Cluster Headaches</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral: For immediate release formulations, administer 240 mg in three divided doses; if this dose does not produce an adequate response, increase the dose by 80 mg every 1 to 2 weeks until symptoms have alleviated or adverse reactions occur.<xref ref-type="bibr" rid="article-31106.r16">[16]</xref><xref ref-type="bibr" rid="article-31106.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>PSVT Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dosed orally For immediate release formulations, the usual dosage range is between 240 mg and 480 mg in 3 to 4 divided doses.<xref ref-type="bibr" rid="article-31106.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ongoing Management of SVT</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For&#x000a0;immediate release formulations, administer an initial dose of 120 mg in divided doses; the maximum&#x000a0;maintenance dose is 480 mg/day.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Acute Treatment of Supraventricular Tachycardia</bold>
</p>
        <p>
<bold>ACLS Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer 2.5 to 5 mg over 2 minutes (over 3 minutes in geriatric patients) administer a second dose of 5 to 10 mg (approximately&#x000a0;0.15 mg/kg) may be given 15 to 30 minutes after the initial dose only if: the patient does not experience any adverse reactions but does not respond to initial treatment.<xref ref-type="bibr" rid="article-31106.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>The maximum total dose is 20 to 30 mg.<xref ref-type="bibr" rid="article-31106.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>ACC/AHA/HRS SVT Guidelines</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Administer 5 to 10 mg (0.075 to 0.15 mg/kg) over 2 minutes</p>
          </list-item>
          <list-item>
            <p>If the patient has no response to this dose, a second dose can be given 30 minutes after the initial dose, followed by an infusion of&#x000a0;0.005 mg/kg/minute.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31106.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gingival hyperplasia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Constipation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Peripheral edema</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Dyspepsia</p>
          </list-item>
        </list>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>May cause first-degree AV block; higher degrees of AV block could occur in patients with sick sinus syndrome - consider a dosage reduction or discontinue verapamil therapy.<xref ref-type="bibr" rid="article-31106.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>It is considered contraindicated in patients with wide complex tachycardias unless it can be proven to be supraventricular in origin; severe hypotension could occur upon administration.<xref ref-type="bibr" rid="article-31106.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Avoid use in patients with heart failure, particularly heart failure with a reduced ejection fraction, due to a higher risk than benefit in using calcium channel blockers overall.<xref ref-type="bibr" rid="article-31106.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Use with caution in patients with HCM with outflow tract obstruction, including those:
<list list-type="bullet"><list-item><p>With high gradients</p></list-item><list-item><p>Advanced heart failure</p></list-item><list-item><p>Sinus bradycardia</p></list-item><list-item><p>Verapamil should not be used in those with HCM and systemic hypotension or severe difficulty breathing at rest.<xref ref-type="bibr" rid="article-31106.r22">[22]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Verapamil can cross the placenta.</p>
          </list-item>
          <list-item>
            <p>Pregnancy Category C<xref ref-type="bibr" rid="article-31106.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Use during pregnancy may cause adverse effects on the fetus(e.g., bradycardia, heart block, hypotension)</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Women with&#x000a0;HCM controlled with verapamil before pregnancy may continue therapy, but it is recommended to monitor the fetus for slow heart rate, low blood pressure, and heart block.<xref ref-type="bibr" rid="article-31106.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>&#x000a0;It may be used intravenously for the acute treatment of SVT in pregnant women when adenosine or beta-blockers are ineffective or contraindicated. Verapamil may also be used for the ongoing management of SVT in highly symptomatic patients; the recommendation is for the lowest effective dose; avoid use during the first trimester if possible.<xref ref-type="bibr" rid="article-31106.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>If treatment for hypertension during pregnancy is needed, it is recommended to change to an alternative agent. (ACOG 2013)<xref ref-type="bibr" rid="article-31106.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Breast-Feeding</bold>
</p>
        <p>Although verapamil is present in breast milk, the relative infant dose of verapamil is less than or equal to 1% of the weight-adjusted maternal dose, which is below the required RID limit of less than 10 %.<xref ref-type="bibr" rid="article-31106.r25">[25]</xref><xref ref-type="bibr" rid="article-31106.r26">[26]</xref> Therefore, breastfeeding is acceptable for verapamil, though some manufacturers are against it.<xref ref-type="bibr" rid="article-31106.r27">[27]</xref><xref ref-type="bibr" rid="article-31106.r28">[28]</xref><xref ref-type="bibr" rid="article-31106.r29">[29]</xref><xref ref-type="bibr" rid="article-31106.r25">[25]</xref> &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>The authors of several case reports calculated the RID of verapamil following maternal use of verapamil 80 to 120 mg three times daily in women less than or equal to 3 months postpartum. Adverse events were not observed in breastfed infants.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31106.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Oral Formulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If the patient has hypersensitivity to verapamil or any component in the verapamil formulation (immediate-release or extended-release)</p>
          </list-item>
          <list-item>
            <p>Severe dysfunction of the left ventricle</p>
          </list-item>
          <list-item>
            <p>Severe hypotension, defined as a systolic blood pressure reading of less than 90 mmHg or cardiogenic shock (except in patients with a functioning artificial ventricular pacemaker)</p>
          </list-item>
          <list-item>
            <p>Sick sinus syndrome and second or third-degree atrioventricular block (the main exception being in patients who have a functioning artificial ventricular pacemaker)</p>
          </list-item>
          <list-item>
            <p>Atrial flutter/fibrillation with an accessory bypass tract (Lown-Ganong-Levine syndrome, Wolff-Parkinson-White [WPW] syndrome)</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous Formulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe heart failure (unless the heart failure results from a supraventricular tachycardia responsive to verapamil)</p>
          </list-item>
          <list-item>
            <p>Concomitant use of intravenous&#x000a0;beta-blockers</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31106.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The clinician should monitor their blood pressure, heart rate, and liver function tests for patients who are on verapamil.</p>
        <p>
<bold>Goals of Therapy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Blood pressure is an essential indicator of how the patient with confirmed hypertension is doing with verapamil. The ASCVD risk and comorbidities of the patient&#x000a0;require&#x000a0;an evaluation to evaluate the specific blood pressure goal for the patient.<xref ref-type="bibr" rid="article-31106.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>If the patient with confirmed hypertension has known cardiovascular disease or a 10-year ASCVD risk greater than or equal to 10%, then the recommended target blood pressure is less than 130/80 mm Hg - for patients without markers of increased ASCVD risk, a target blood pressure less than 130/80 is not a recommendation but is a reasonable goal.<xref ref-type="bibr" rid="article-31106.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Special Populations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal Impairment: </bold>If repeated intravenous injections are necessary for therapy, monitor blood pressure, and PR readings &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Liver Impairment (Cirrhosis): </bold>Monitor ECG and reduce dose to:
<list list-type="bullet"><list-item><p>20% in oral formulations</p></list-item><list-item><p>50% in intravenous formulations</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31106.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Like all calcium channel blockers, an overdose of verapamil can lead to negative inotropic and chronotropic effects, dilation of arterial vasculature, and hypotension. Additionally, verapamil&#x02019;s blockade of slow calcium channels in pancreatic beta cells can lead to inhibited insulin release, thereby causing hyperglycemia. If a patient experiences bradycardia with hypotension/metabolic acidosis and hyperglycemia is indicative of verapamil toxicity. The most serious complications from a verapamil overdose are bradycardia and hypotension, as both can lead to death if the patient is left untreated.</p>
        <p>If a patient presents with verapamil toxicity within 1 hour, two decontamination procedures exist; gastric lavage and single-dose activated charcoal.<xref ref-type="bibr" rid="article-31106.r31">[31]</xref><xref ref-type="bibr" rid="article-31106.r32">[32]</xref>&#x000a0;If a patient presents with verapamil toxicity after 1 hour of ingestion has elapsed, whole bowel irrigation using polyethylene glycol electrolyte solution is a viable decontamination procedure.<xref ref-type="bibr" rid="article-31106.r33">[33]</xref> According to experimental and clinical studies, ipecac and cathartics have not proven beneficial decontamination procedures.<xref ref-type="bibr" rid="article-31106.r33">[33]</xref><xref ref-type="bibr" rid="article-31106.r34">[34]</xref><xref ref-type="bibr" rid="article-31106.r35">[35]</xref></p>
        <p>
<bold>Treatment of Calcium Channel Blocker Overdose</bold>
<xref ref-type="bibr" rid="article-31106.r36">[36]</xref>
</p>
        <p>Patients with symptoms should undergo treatment with the prioritization of first-line therapy. Determination of which treatment is first-line depends upon the desired effect to include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous calcium</p>
          </list-item>
          <list-item>
            <p>High dose insulin monotherapy (in patients with myocardial dysfunction)</p>
          </list-item>
          <list-item>
            <p>Norepinephrine or epinephrine if the patient is suffering from shock (norepinephrine is preferable in patients with vasodilatory shock)</p>
          </list-item>
        </list>
        <p>Patients refractory to first-line therapies:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fat emulsion therapies</p>
          </list-item>
          <list-item>
            <p>Incremental doses of high dose insulin therapy &#x02013; in patients with myocardial dysfunction</p>
          </list-item>
          <list-item>
            <p>Use of a pacemaker &#x02013; in patients with unstable bradycardia/high-grade AV block without significant alteration in cardiac inotropy</p>
          </list-item>
        </list>
        <p>Patients with refractory shock/precardiac-arrest:&#x000a0; &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Incremental doses of high dose insulin</p>
          </list-item>
          <list-item>
            <p>Fat emulsion therapy</p>
          </list-item>
          <list-item>
            <p>Venoarterial extracorporeal membrane oxygenation (only to be used when the refractory shock contains a significant cardiogenic component)</p>
          </list-item>
        </list>
        <p>Administration of calcium chloride or calcium gluconate in symptomatic patients is another therapeutic alternative. Calcium chloride is used in nonacidotic patients because it delivers three times the amount of calcium than calcium gluconate. In contrast, calcium gluconate is used in acidotic patients because calcium chloride could worsen the acidosis. Both calcium formulations must have IV administration. &#x000a0;</p>
      </sec>
      <sec id="article-31106.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals (pharmacists, nurses, mid-level practitioners, and doctors) who prescribe and distribute this medication should be aware of the side effects and sound-alike look-alike issues between the verapamil brand names; these concerns require monitoring of heart rate and blood pressure. Pharmacists should educate patients&#x000a0;regarding the drug's side effects&#x000a0;and how to identify and what to do if they&#x000a0;experience them. Further, they should keep track of other medications that the patient is taking to avoid drug-drug interactions. Pharmacists should also educate doctors and nurses on the differences between oral and IV dosing and exercise caution when converting from one route to another. When a&#x000a0;clinician decides to switch from oral formulation to intravenous formulation, the total daily dose of verapamil will remain the same unless the strength of the formulation does not allow for direct mg for mg conversion. Therefore, nurses and clinicians should engage the pharmacist when prescribing or counseling on the dosing and administration of the various formulations, and nursing should understand this information for their counseling. This type of interprofessional communication among healthcare team members will improve outcomes using verapamil. [Level 5]</p>
      </sec>
      <sec id="article-31106.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31106&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31106">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31106/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31106">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31106.s11">
        <title>References</title>
        <ref id="article-31106.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsterdam</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Kontos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Liebson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smalling</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Zieman</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>23</day>
            <volume>64</volume>
            <issue>24</issue>
            <fpage>e139</fpage>
            <page-range>e139-e228</page-range>
            <pub-id pub-id-type="pmid">25260718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weaver-Agostoni</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Cluster headache.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Jul</month>
            <day>15</day>
            <volume>88</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-8</page-range>
            <pub-id pub-id-type="pmid">23939643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice</collab>
              <collab>American Association for Thoracic Surgery</collab>
              <collab>American Society of Echocardiography</collab>
              <collab>American Society of Nuclear Cardiology</collab>
              <collab>Heart Failure Society of America</collab>
              <collab>Heart Rhythm Society</collab>
              <collab>Society for Cardiovascular Angiography and Interventions</collab>
              <collab>Society of Thoracic Surgeons</collab>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fifer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ommen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rakowski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Udelson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>142</volume>
            <issue>6</issue>
            <fpage>e153</fpage>
            <page-range>e153-203</page-range>
            <pub-id pub-id-type="pmid">22093723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Heart Rhythm</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>e190</fpage>
            <page-range>e190-e252</page-range>
            <pub-id pub-id-type="pmid">29097320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basile</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of existing and newer calcium channel blockers in the treatment of hypertension.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>621</fpage>
            <page-range>621-29; quiz 630-1</page-range>
            <pub-id pub-id-type="pmid">15538095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pasko</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>3-4</issue>
            <fpage>302</fpage>
            <page-range>302-16</page-range>
            <pub-id pub-id-type="pmid">11149130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Fleg</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pepine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Artinian</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ferdinand</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Forciea</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Frishman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Jaigobin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kostis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reisin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Schocken</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wesley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>ACCF Task Force</collab>
            </person-group>
            <article-title>ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>May</month>
            <day>31</day>
            <volume>123</volume>
            <issue>21</issue>
            <fpage>2434</fpage>
            <page-range>2434-506</page-range>
            <pub-id pub-id-type="pmid">21518977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibbons</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Deedwania</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fraker</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Gardin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Pasternak</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SV</given-names>
              </name>
              <collab>American College of Cardiology</collab>
              <collab>American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina)</collab>
            </person-group>
            <article-title>ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina).</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2003</year>
            <month>Jan</month>
            <day>01</day>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>159</fpage>
            <page-range>159-68</page-range>
            <pub-id pub-id-type="pmid">12570960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>e199</fpage>
            <page-range>e199-267</page-range>
            <pub-id pub-id-type="pmid">24682347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Sanoski</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Just</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Bauman</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.</article-title>
            <source>Pharmacotherapy</source>
            <year>1997</year>
            <season>Nov-Dec</season>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1238</fpage>
            <page-range>1238-45</page-range>
            <pub-id pub-id-type="pmid">9399606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Ackerman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Callans</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Dickfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kay</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Matlock</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Myerburg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>138</volume>
            <issue>13</issue>
            <fpage>e272</fpage>
            <page-range>e272-e391</page-range>
            <pub-id pub-id-type="pmid">29084731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Blaszyk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology.</article-title>
            <source>Am Heart J</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>126</volume>
            <issue>5</issue>
            <fpage>1126</fpage>
            <page-range>1126-33</page-range>
            <pub-id pub-id-type="pmid">8237755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality.</article-title>
            <source>Br Heart J</source>
            <year>1992</year>
            <month>Oct</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>392</fpage>
            <page-range>392-7</page-range>
            <pub-id pub-id-type="pmid">1449923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Camm</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia.</article-title>
            <source>Pacing Clin Electrophysiol</source>
            <year>1992</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11 Pt 2</issue>
            <fpage>2122</fpage>
            <page-range>2122-6</page-range>
            <pub-id pub-id-type="pmid">1279611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>May</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ndor</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <collab>EFNS Task Force</collab>
            </person-group>
            <article-title>EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias.</article-title>
            <source>Eur J Neurol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>1066</fpage>
            <page-range>1066-77</page-range>
            <pub-id pub-id-type="pmid">16987158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robbins</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines.</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>1093</fpage>
            <page-range>1093-106</page-range>
            <pub-id pub-id-type="pmid">27432623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Deal</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Estes</surname>
                <given-names>NAM</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldberger</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Indik</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Olshansky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Apr</month>
            <day>05</day>
            <volume>67</volume>
            <issue>13</issue>
            <fpage>e27</fpage>
            <page-range>e27-e115</page-range>
            <pub-id pub-id-type="pmid">26409259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kronick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Shuster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Callaway</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kudenchuk</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Silvers</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Passman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sinz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</article-title>
            <source>Circulation</source>
            <year>2010</year>
            <month>Nov</month>
            <day>02</day>
            <volume>122</volume>
            <issue>18 Suppl 3</issue>
            <fpage>S729</fpage>
            <page-range>S729-67</page-range>
            <pub-id pub-id-type="pmid">20956224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>WRITING COMMITTEE MEMBERS</collab>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Geraci</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Horwich</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Riegel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Wilkoff</surname>
                <given-names>BL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>128</volume>
            <issue>16</issue>
            <fpage>e240</fpage>
            <page-range>e240-327</page-range>
            <pub-id pub-id-type="pmid">23741058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fifer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ommen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rakowski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Udelson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
              <collab>American Association for Thoracic Surgery</collab>
              <collab>American Society of Echocardiography</collab>
              <collab>American Society of Nuclear Cardiology</collab>
              <collab>Heart Failure Society of America</collab>
              <collab>Heart Rhythm Society</collab>
              <collab>Society for Cardiovascular Angiography and Interventions</collab>
              <collab>Society of Thoracic Surgeons</collab>
            </person-group>
            <article-title>2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2011</year>
            <month>Dec</month>
            <day>13</day>
            <volume>124</volume>
            <issue>24</issue>
            <fpage>e783</fpage>
            <page-range>e783-831</page-range>
            <pub-id pub-id-type="pmid">22068434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Hypertrophic obstructive cardiomyopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>25</day>
            <volume>350</volume>
            <issue>13</issue>
            <fpage>1320</fpage>
            <page-range>1320-7</page-range>
            <pub-id pub-id-type="pmid">15044643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>KI</given-names>
              </name>
            </person-group>
            <article-title>Treatment of tachyarrhythmias during pregnancy and lactation.</article-title>
            <source>Eur Heart J</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>458</fpage>
            <page-range>458-64</page-range>
            <pub-id pub-id-type="pmid">11237540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <article-title>Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&#x02019; Task Force on Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>1122</fpage>
            <page-range>1122-1131</page-range>
            <pub-id pub-id-type="pmid">24150027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Withers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhamra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Verapamil and breast-feeding.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1986</year>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-6</page-range>
            <pub-id pub-id-type="pmid">3709626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy for breast-feeding women.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Jul</month>
            <day>13</day>
            <volume>343</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-26</page-range>
            <pub-id pub-id-type="pmid">10891521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andersen</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Excretion of verapamil in human milk.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1983</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-80</page-range>
            <pub-id pub-id-type="pmid">6628513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bondesson</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mattiasson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Verapamil and norverapamil in plasma and breast milk during breast feeding.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1987</year>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>625</fpage>
            <page-range>625-7</page-range>
            <pub-id pub-id-type="pmid">3830249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Unno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Iwama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Level of verapamil in human milk.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1984</year>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>657</fpage>
            <page-range>657-8</page-range>
            <pub-id pub-id-type="pmid">6468488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aleyadeh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hutt-Centeno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Hypertension guidelines: Treat patients, not numbers.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-56</page-range>
            <pub-id pub-id-type="pmid">30624184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Hoppu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Bedry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000f6;jer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thanacoody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <collab>American Academy of Clinical Toxicology</collab>
              <collab>European Association of Poisons Centres and Clinical Toxicologists</collab>
            </person-group>
            <article-title>Position paper update: gastric lavage for gastrointestinal decontamination.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>140</fpage>
            <page-range>140-6</page-range>
            <pub-id pub-id-type="pmid">23418938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chyka</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Seger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krenzelok</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>JA</given-names>
              </name>
              <collab>American Academy of Clinical Toxicology</collab>
              <collab>European Association of Poisons Centres and Clinical Toxicologists</collab>
            </person-group>
            <article-title>Position paper: Single-dose activated charcoal.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2005</year>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-87</page-range>
            <pub-id pub-id-type="pmid">15822758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanacoody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>H&#x000f6;jer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoppu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bedry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">25511637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <collab>American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention</collab>
            <article-title>Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention.</article-title>
            <source>Pediatrics</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>112</volume>
            <issue>5</issue>
            <fpage>1182</fpage>
            <page-range>1182-5</page-range>
            <pub-id pub-id-type="pmid">14595067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;jer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Hoppu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thanacoody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bedry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <collab>American Academy of Clinical Toxicology</collab>
              <collab>European Association of Poison Centres and Clinical Toxicologists</collab>
            </person-group>
            <article-title>Position paper update: ipecac syrup for gastrointestinal decontamination.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>134</fpage>
            <page-range>134-9</page-range>
            <pub-id pub-id-type="pmid">23406298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31106.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anseeuw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Gilchrist</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lalibert&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Muscedere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sinuff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rieder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.</article-title>
            <source>Crit Care Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>e306</fpage>
            <page-range>e306-e315</page-range>
            <pub-id pub-id-type="pmid">27749343</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
